Abstract:Countless expectations converge in the multidisciplinary endeavour for the search and development of effective and safe drugs in fighting cancer. Although they still embody a minority of the pharmacological agents currently in clinical use, metal-based complexes have great yet unexplored potential, which probably hides forthcoming anticancer drugs. Following the historical success of cisplatin and congeners, but also taking advantage of conventional chemotherapy limitations that emerged with applications in the clinic, the design and development of non-platinum metal-based chemotherapeutics, either as drugs or prodrugs, represents a rapidly evolving field wherein candidate compounds can be fine-tuned to access interactions with druggable biological targets. Moving in this direction, over the last few decades platinum family metals, e.g., ruthenium and palladium, have been largely proposed. Indeed, transition metals and molecular platforms where they originate are endowed with unique chemical and biological features based on, but not limited to, redox activity and coordination geometries, as well as ligand selection (including their inherent reactivity and bioactivity). Herein, current applications and progress in metal-based chemoth are reviewed. Converging on the recent literature, new attractive chemotherapeutics based on transition metals other than platinum—and their bioactivity and mechanisms of action—are examined and discussed. A special focus is committed to anticancer agents based on ruthenium, palladium, rhodium, and iridium, but also to gold derivatives, for which more experimental data are nowadays available. Next to platinum-based agents, ruthenium-based candidate drugs were the first to reach the stage of clinical evaluation in humans, opening new scenarios for the development of alternative chemotherapeutic options to treat cancer.

Metal-N-heterocyclic carbene complexes as anti-tumor agents

A promising future of metal‐N‐heterocyclic carbene complexes in medicinal chemistry: The emerging bioorganometallic antitumor agents

Research progress of natural product-conjugated platinum and gold complexes as potential antitumor agents

Metal-based Anticancer Chemotherapeutic Agents.

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship

Towards the Rational Design of Platinum(ii) and Gold(iii) Complexes As Antitumour Agents

Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment

Biomedical applications of multinuclear Pt(II)/Ru(II)/Ir(III) metallo-supramolecular assemblies for intensive cancer therapy

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.

The Therapeutic Potential in Cancer of Terpyridine‐Based Metal Complexes Featuring Group 11 Elements

Antitumor properties and mechanisms of mitochondria-targeted Ag(I) and Au(I) complexes containing N-heterocyclic carbenes derived from cyclophanes

Recent Advances in Ruthenium and Platinum Based Supramolecular Coordination Complexes for Antitumor Therapy

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Research Progress of Metal Anticancer Drugs

Metal Complexes of Natural Product Like-compounds with Antitumor Activity.

Metal Complexes Induced Ferroptosis for Anticancer Therapy

Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs

Multi-Target Metal-Based Anticancer Agents

Catalytic and Pharmacological Activity

Homo and heterometallic ruthenium and platinum complexes with multiple targets for therapeutic applications: a review